Mentara Bio, a portfolio company of Stratos BioCapital, is at the forefront of developing innovative treatments for neurological disorders. By integrating cutting-edge brain science with advanced technologies, Mentara Bio aims to address unmet medical needs in conditions such as epilepsy and neurodegenerative diseases.
Innovative Research and Development
Mentara Bio’s mission is to harness advanced neuroscience to create therapies that improve neural function. The company’s approach involves combining clinically validated research on neuroinflammation and neurogenesis with precision medicine technologies to develop novel treatments.
Lead Program: MN-301 for Epilepsy
The company’s lead candidate, MN-301, is a glutamate modulator targeting dysregulated glutamatergic pathways in epilepsy. By stabilizing neuronal firing, MN-301 aims to reduce seizure occurrences with a favorable safety profile. Mentara Bio plans to commence a Phase 2 clinical trial of MN-301 for the treatment of epilepsy.
Expanding the Pipeline
Beyond epilepsy, Mentara Bio is exploring additional neurological disorders involving neurotransmitter imbalances, such as Huntington’s disease, Alzheimer’s disease, and chronic pain syndromes. Utilizing advanced research platforms, the company is investigating innovative compounds and therapeutic approaches to address these challenging conditions.
Looking Ahead
With the support of Stratos BioCapital, Mentara Bio is advancing its pipeline toward clinical trials, aiming to bring novel neurological therapies to patients in need.
For more updates, visit https://mentarabio.com.